Key developments:
- Sinovac held a disputed shareholder meeting on July 9 that elected a new board backed by SAIF Partners
- A rival faction led by Li Jiaqiang (李嘉强) declared the new board illegitimate amidst legal challenges
- The company announced a record $7.4 billion cash dividend triggering intensified power struggles
- Major investors strategize for board control ahead of crucial Nasdaq compliance deadlines
Corporate Governance in Crisis
The ongoing power struggle at Sinovac Biotech reached a critical juncture on July 9 when the vaccine maker convened a special shareholders’ meeting marked by controversy. According to SAIF Partners—one of Sinovac’s key investors—shareholders voted to dismiss the current board and elect ten new directors proposed by SAIF, including SAIF managing partner Yan Yan (阎焱) as chairman and former chairman Yin Weidong (尹卫东) as CEO. However, within hours of the vote, representatives of Li Jiaqiang’s (李嘉强) faction denounced the proceedings as illegitimate, claiming the meeting had been officially adjourned prior to any voting. This dispute plunges Sinovac into renewed governance chaos exactly six months after Li’s group had taken control following a British judiciary ruling.
The Boardroom Legitimacy Debate
Competing Claims Emerge
Li Jiaqiang’s team contends that following his announcement of recent rulings from Antigua’s courts during the July 9 meeting, he formally adjourned proceedings before any voting could occur. A spokesperson for his faction stated: “SAIF’s claim about continuing the meeting and self-appointing a new board is false and legally baseless.” They maintain that the current four-member board (comprising Li, Lu Yulin, Sven Borho, and Geoffrey Hsu) remains Sinovac’s only lawful governing body.
SAIF-Led Board’s Counterargument
The new board claims 54.71% of voting power validated their appointments during the first convened session. In response to the challenge, SAIF board representatives announced plans to “take necessary measures to defend the election results” and enforce operational normalization. Significantly, both factions agree on one strategic priority—appointing new auditors to satisfy Nasdaq requirements that threaten Sinovac with imminent delisting. Nasdaq requires Sinovac to submit compliant financial statements after their shares were suspended since April 2025.
Legal Complexities Cloud Proceedings
Stock Validity Dispute
The battle hinges partly on the validity of 11.8 million shares originating from a 2018 private investment (PIPE transaction) involving Vivo Capital and Shanggang Capital. On July 7, Antigua’s High Court temporarily restricted these shares from voting pending jurisdictional review. Despite this, appellate permission allowed both funds to vote at the meeting—a point Li’s team contests as invalid.
Contradictory Polling Data
Georgeson advisory executive William Fiske indicated preliminary vote counts favored Li’s board “overwhelmingly,” emphasizing that suspension of Antigua’s injunction altered outcomes. With no independent verification of results, both factions mobilize arguments across multiple legal jurisdictions including Antigua, UK courts overseeing previous litigation, and US regulatory bodies. The contested shares’ dividends currently sit in third-party escrow awaiting resolution.
The Massive Dividend Catalyst
Payment Mechanics
The start of Sinovac’s 74-billion payout coincided strategically with the shareholder meeting: A $55-per-share installment launched July 10, totaling approximately $534 million RMB ($74 million USD). Following payments could distribute between $103-$124 per share, potentially consuming 70% of Sinovac’s $10.3 billion cash reserves. Top beneficiaries include:
- Li Jiaqiang/1Globe Capital: $688 million
- SAIF Partners: $593 million
- Yin Weidong: $350 million
- Vivo Capital & Shanggang Capital: $320 million each
Dividend’s Strategic Purpose
Li’s supporters frame the payout as compensatory after years without shareholder distributions despite massive dividends paid to foreign investors holding direct stakes in Sinovac’s operating subsidiary Beijing Sinovac Research. They argue that as a holding company, Sinovac rationally deploy capital without disrupting vaccine operations. Vivo Capital counters in a June public letter: “Suggestions that we oppose dividends are false—we simply demand legality.”
Historical Power Struggles Resurface
The current confrontation extends Sinovac’s heritage of shareholder conflicts tracing back to founder Yin Weidong’s fallout with original partner Pan Aihua. Li Jiaqiang gradually became Sinovac’s largest investor through secondary market purchases after Pan faced criminal charges. Currently holding 32.3% via Singapore-based 1Globe Capital as verified by SEC filings, Li consolidated power in January 2025 when UK Privy Council rulings installed his board.
Delisting Deadline Looming
Amid disputes, Sinovac’s Nasdaq compliance remains unresolved. Market regulations require audited financials submission within 180 days after trading suspension—a timeline expiring October 2025. Both boards agree that retaining the exchange listing requires immediate auditor appointment and management transparency. Failure would trigger delisting just as COVID-19 booster demand revives vaccine revenue streams globally.
Corporate Governance Quagmire
Understanding Sinovac requires distinguishing between two legal entities:
- Sinovac Biotech Ltd (contested holding company)
- Beijing Sinovac Biotech Co (operating subsidiary producing vaccines)
Resolution Pathway Forward
The fiercest corporate clash in China’s biotech sector shows no swift resolution. Li Jiaqiang affirms through associates that “amicable communication channels remain open” and insists he seeks experienced governance without permanent chairmanship. SAIF’s board emphasizes launching dividends while defending their position in multiple jurisdictions.
The outcome will resonate through China’s entrepreneurial finance systems. Investors must scrutinize Nasdaq filings and Antiguan legal proceedings while Sinovac’s warring shareholders convene working-level negotiations. As both factions regroup statutory arguments ahead potential court decisions this fall, shareholders weighing long-term value must prioritize Sinovac’s operational independence over tactical cash incentives regardless of board alignment.